Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for EVOLOCUMAB
- Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism
- Evolocumab in STEMI
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
- Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
- Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)
- Safety and Efficacy of Evolocumab in Ischemic Stroke
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1
- Effect of PCSK9 Inhibitors on Chronic Total Occlusions
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
- High-Resolution Assessment of Extracranial Plaques in Evolocumab Treatment
- The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
- Evolocumab Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
- EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
- A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- Effect of PCSK9 InhibitorS On Calcific Aortic Valve DiseasE
- Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
- Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19
- The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
- Cholesterol Disruption in Combination With FOLFIRINOX in Patients With Metastatic Pancreatic Adenocarcinoma
- CARotid plaqUe StabilizatiOn and Regression With Evolocumab.
- Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
- Effect of Evolocumab on Coronary Plaque Characteristics
- Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"
- PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
- Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
- Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment
- Lipid Management in Renal Transplant Recipients Using Evolocumab.
- A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy
- Evolocumab In Advanced Chronic Kidney Disease Trial
- Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
- CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
- Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion
- Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)
- Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease
- Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody
- PCSK9 Inhibitor Treatment for Patients With SPG5
- Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
- Evolocumab in Patients With Acute MI
- PET Imaging of Inflammation and Lipid Lowering Study
- The CHORAL Flow Study
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
- Impact of Evolocumab in Cardiac Transplant Patients With CAV
- EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
- Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)
- Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
- Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)
- The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
- Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia
- EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot
- Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
- Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by CCTA and Microcalcification by F18-NaF PET
- Effect of Evolocumab on Vascular Function
- Imaging of Coronary Plaques in Participants Treated With Evolocumab
- Evolocumab in Acute Coronary Syndrome
- Effect of Evolocumab on Coronary Endothelial Function
- Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia
- Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Impact of LDL-cholesterol Lowering on Platelet Activation
- EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
- Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention
- Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
- Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
- Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
- An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
- Evolocumab Pregnancy Exposure Registry
- Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
- Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
- Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
- Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
- Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
- Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
- Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
- Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
- GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
- Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
- Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
- Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
- Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
- Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Clinical trials list
click for details